Checkpoint Therapeutics Q4 2019 Earnings Report
Key Takeaways
Checkpoint Therapeutics reported its full-year 2019 financial results, highlighting the progress of cosibelimab's clinical trial and the confirmation from the FDA regarding the registration submission pathway in CSCC. The company also closed a $20 million financing to extend its cash runway.
Advanced the development of cosibelimab, which is in a registration-enabling Phase 1 clinical trial.
Received confirmation from the FDA of the registration submission pathway in CSCC based on the ongoing clinical trial.
Closed on gross proceeds of approximately $20 million in a November financing.
Cosibelimab has the potential to be a market disrupting product through its differentiated two-fold mechanism of action.
Checkpoint Therapeutics
Checkpoint Therapeutics
Forward Guidance
The press release contains forward-looking statements regarding plans to submit BLAs, the potential differentiation of cosibelimab, the company's growth strategy, and product development programs.